GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                                     
                            
                            
                            
                                 Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Neoceptin-3 is a synthetic molecular Toll-like receptor 4 (TLR4) agonist mimetic [2]. It bears no structural similarity with the endogenous ligand for TLR4, LPS, and in fact the biologically relevant molecular target for neoseptin-3 is the TLR4/MD-2 (LY96) complex [3]. This is one of the compounds claimed in patent WO2014131023 [1] in which the compound's action as an immune system adjuvant is claimed. Neoceptin-3 is claimed for its ability to elicit an immune response via TLR4, without the toxicity exhibited by LPS [3]. The S stereoisomer is  specified in [3]. The R stereoisomer is represented by PubChem CID 90371379.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||